CIT-013 has a number of life cycle opportunities and after careful analysis we have chosen SLE as the first indication for which Citryll intends to obtain clinical Proof of Concept that CIT-013 can inhibit NET formation and promote NET clearance through NET and SLE biomarkers as well as exploratory clinical efficacy readouts.
A confirmatory SAD study for determining safety, tolerance and PK will start in the summer of 2021. The SAD study will be followed by a PD study consisting of a LPS nano-dosing challenge study to determine PD activity of CIT-013 in human subjects. This will be followed by an MAD study in SLE patients. Additionally Citryll is preparing for a second patient study for a different indication.